ModerateCentrally acting psychostimulant×NSAID, propionic acid derivative
Updated · Methodology
Mechanism
Cytochrome P450 enzymes do not metabolise methylphenidate to a clinically relevant extent, and methylphenidate does not markedly inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A. It is broken down mainly to alpha-phenyl-piperidine acetic acid, which has little or no activity and is excreted in the urine (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The liver converts naproxen to 6-O-desmethylnaproxen, and about 95% of the dose is excreted in the urine, mostly as conjugates (naproxen SmPC, AEMPS). The documents say nothing about either drug changing the metabolism of the other. What the two drugs share is an effect on blood pressure. Methylphenidate may increase blood pressure and heart rate (methylphenidate SmPC, AEMPS; methylphenidate label, US Food and Drug Administration, FDA). Non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can lead to new hypertension or worsen existing hypertension (naproxen label, FDA).
Symptoms
The documents describe no symptoms specific to this combination. Central nervous system stimulants, including methylphenidate, may increase blood pressure by about 2–4 mm Hg on average and heart rate by about 3–6 beats per minute. Some people may have larger increases (methylphenidate label, US Food and Drug Administration, FDA). Palpitations, pressing chest pain, unexplained syncope or dyspnoea during treatment call for a prompt specialist cardiac evaluation (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Naproxen can cause or worsen hypertension and can cause fluid retention and oedema (naproxen label, FDA; naproxen SmPC, AEMPS).
Management
No document contraindicates the combination, but methylphenidate is used with caution together with any medicine that also raises blood pressure (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Naproxen can cause or worsen hypertension (naproxen label, US Food and Drug Administration, FDA). During methylphenidate treatment, blood pressure and pulse are recorded at each dose adjustment and then at least every 6 months. With repeated tachycardia, arrhythmia or systolic blood pressure above the 95th percentile, methylphenidate is stopped and referral to a cardiologist is considered (methylphenidate SmPC, AEMPS). In people taking medicines that raise blood pressure, neurological signs and symptoms are assessed at every visit after methylphenidate is started (methylphenidate SmPC, AEMPS). Blood pressure is monitored from the start of naproxen treatment and throughout its course (naproxen label, FDA). Methylphenidate is contraindicated in severe hypertension (methylphenidate SmPC, AEMPS). In uncontrolled hypertension, naproxen is prescribed only if the doctor considers the benefit-risk balance favourable (naproxen SmPC, AEMPS). Naproxen is taken at the lowest effective dose for the shortest time (naproxen SmPC, AEMPS). The documents give no specific dose adjustment for this combination (methylphenidate and naproxen SmPCs, AEMPS; methylphenidate and naproxen labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Naproxeno (nº registro 56267), secciones 4.2, 4.3, 4.4 y 4.5 (2025)– AEMPS, CIMA, Naprosyn 500 mg comprimidos, nº registro 56267, revisión 02/2025, secciones 4.2, 4.3, 4.4 y 4.5
- FDA: Naproxen tablets and naproxen sodium tablets (naproxen) prescribing information (2025)– FDA, DailyMed setid 6c5bb008-e66f-4ef0-bf84-aca7eb5983e9 (Glenmark Pharmaceuticals USA), revised 12/2025, sections 7, 12.2
- AEMPS: Ficha técnica: Metilfenidato (nº registro 65148), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65148 (Concerta 18 mg, Janssen), revisión 03/2026, secciones 4.4, 4.5 y 5.1
- FDA: CONCERTA (methylphenidate hydrochloride) prescribing information (2026)– FDA, DailyMed setid 1a88218c-5b18-4220-8f56-526de1a276cd (Janssen), revisión 04/2026 (versión 30), secciones 4, 5.3 y 7